These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 29079323

  • 21. Fluoroquinolone prophylaxis in patients with neutropenia at high risk of serious infections: Exploring pros and cons.
    Singh N, Thursky K, Maron G, Wolf J.
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14152. PubMed ID: 37746769
    [Abstract] [Full Text] [Related]

  • 22. Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients.
    Ziegler M, Landsburg D, Pegues D, Bilker W, Gilmar C, Kucharczuk C, Gorman T, Bink K, Moore A, Fitzpatrick R, Stadtmauer EA, Mangan P, Kraus K, Han JH.
    Biol Blood Marrow Transplant; 2019 May; 25(5):1004-1010. PubMed ID: 30481595
    [Abstract] [Full Text] [Related]

  • 23. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
    Bow EJ.
    Curr Opin Infect Dis; 2011 Dec; 24(6):545-53. PubMed ID: 22001945
    [Abstract] [Full Text] [Related]

  • 24. Prevention of febrile neutropenia: use of prophylactic antibiotics.
    Cullen M, Baijal S.
    Br J Cancer; 2009 Sep; 101 Suppl 1(Suppl 1):S11-4. PubMed ID: 19756000
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma.
    Guare EG, Hale CM, Sivik J, Lehman E, Inoue Y, Rakszawski K, Songdej N, Nickolich M, Zheng H, Naik S, Claxton D, Rybka W, Hohl R, Mineishi S, Minagawa K, Paules CI.
    Transpl Infect Dis; 2024 Apr; 26(2):e14241. PubMed ID: 38269469
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies.
    Shinohara A, Yoshiki Y, Masamoto Y, Hangaishi A, Nannya Y, Kurokawa M.
    Leuk Lymphoma; 2013 Apr; 54(4):794-8. PubMed ID: 22978686
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.
    Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, Signorini L, Re A, Carosi G, Rossi G.
    J Antimicrob Chemother; 2008 Mar; 61(3):721-8. PubMed ID: 18218645
    [Abstract] [Full Text] [Related]

  • 34. Counterpoint: routine anti-bacterial prophylaxis is not indicated in neutropenic patients with hematological malignancies.
    Kleinberg M.
    J Natl Compr Canc Netw; 2004 Sep; 2(5):445-51. PubMed ID: 19780253
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients.
    Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, Domingo-Domenech E, Jiménez L, Carratalà J.
    Clin Microbiol Infect; 2013 May; 19(5):474-9. PubMed ID: 22524597
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study.
    Paret R, Le Bourgeois A, Guillerm G, Tessoulin B, Rezig S, Gastinne T, Couturier MA, Boutoille D, Lecomte R, Ader F, Le Gouill S, Ansart S, Talarmin JP, Gaborit B.
    J Antimicrob Chemother; 2022 Aug 25; 77(9):2546-2556. PubMed ID: 35748614
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.